{Reference Type}: Journal Article
{Title}: Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data.
{Author}: Başa Akdoğan B;Aksu K;Koca Kalkan İ;Köycü Buhari G;Özdedeoğlu Ö;Ateş H;Öner Erkekol F;
{Journal}: Tuberk Toraks
{Volume}: 72
{Issue}: 1
{Year}: 2024 Mar
暂无{DOI}: 10.5578/tt.202401795
{Abstract}: UNASSIGNED: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid-sparing drug in patients with CEP.
UNASSIGNED: The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated.
UNASSIGNED: In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed.
UNASSIGNED: Omalizumab can be an effective treatment for CEP and can be used as a steroid-sparing agent.